Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of
human neoplasms. Their clinical success is, however, limited due to severe side effects and …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

Summary Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of
docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC) …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide.
Therefore, improvements in diagnostics and treatments are urgently needed. In this review …

The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …

Resistance to cancer therapy remains a major challenge in clinical oncology. Although the
initial treatment phase is often successful, eventual resistance, characterized by tumour …

Purpose This phase III trial compared the efficacy and safety of albumin-bound paclitaxel
(nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus …

Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease
progression in some patients, leading to progression-free survival (PFS) and overall survival …